Supplementary methods data.

Characteristics of the series of 197 CLL patients with 11q deletion (Table A). Univariate analysis of time to first therapy in 11q- CLL patients with respect to the number of losses detected by FISH: <40% (n = 51) or ≥40% (n = 146) (Table B). Univariate analysis of overall survival in 11q- CLL patients with respect to the number of losses detected by FISH: <40% (n = 51) or ≥40% (n = 146) (Table C). Main clinical and biological characteristics of 25 CLL patients with 11q- with respect to ATM mutational status (Table D). PCR primers used for next-generation sequencing studies (Table E). A: PCR amplification protocol for ATM. B. B: PCR amplification protocol for the remaining genes (Table F). Median frequency of reads generated by next-generation sequencing (NGS) (Table G). A. Time to first therapy (TFT) and B. Overall survival (OS) of the global series of 197 CLL patients with 11q deletion (Fig A), A. Time to first therapy (TFT) and B. Overall survival (OS) of patients with CLL and 11q deletion and a percentage of FISH losses <40%, 41–59% or ≥60% (Fig B). Kaplan-Meier plots of time to first therapy (TFT) (A) and overall survival (OS) (B) from diagnosis for 11q- CLL patients sequenced for NOTCH1 and TP53, respectively (Fig C) (DOC)